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Designing altered peptide ligands to generate specific
immunological reactivity when bound to class I major
histocompatibility complexes is important for both ther-
apeutic and prophylactic reasons. We have previously
shown that two altered peptides, derived from human
immunodeficiency virus (HIV)-reverse transcriptase
(RT) residues 309–317, are more immunogenic in vitro
than the wild-type peptide. One peptide variant, I1Y,
was able to stimulate RT-specific cytotoxic T cells from
the blood of three HIV-infected individuals better than
the wild-type RT peptide. Both I1Y and I1F peptide vari-
ants increase the cell surface half-life of the peptide-
class I complex approximately 3-fold over that of the RT
peptide but have different immunological activities.
These peptides are candidates for the design of vaccines
for HIV due to their increased immunogenicity. To un-
derstand the basis for the increased cell surface stabil-
ity compared with wild-type peptide and to understand
the differences in T cell recognition between I1Y and
I1F, we determined the x-ray crystal structures of the
two class I MHC-peptide complexes. These structures
indicate that the increased cell surface half-life is due to
p-p stacking interactions between Trp-167 of HLA-A2.1
and the aromatic P1 residues of I1F and I1Y. Compari-
son of the structures and modeling potential T cell re-
ceptor (TCR) interactions suggests that T cell interac-
tions and immunogenicity are different between I1Y and
I1F for two reasons. First, subtle changes in the steric
and polar properties of the I1Y peptide affect TCR en-
gagement. Second, water-mediated hydrogen bond in-
teractions between the P1-Tyr and the P4-Glu peptide
residues increase peptide side chain rigidity of residues
critical for TCR engagement.
The cytolytic immune response is a major component of the
body’s defense against viral infection (1). This response is me-
diated by the interaction between the T cell receptor (TCR)1 on
CD81 cytotoxic T lymphocytes (CTLs) and the class I major
histocompatibility complex (MHC) molecules expressed on the
surface of antigen-presenting cells (2). Control of viral infec-
tions such as HIV requires a vigorous CTL response (3).
Class I MHC molecules are trimolecular complexes consist-
ing of an allotype-specific heavy chain, a light chain b2-micro-
globulin, and an endogenously processed peptide. The anti-
genic peptide typically binds with the termini buried in the
peptide-binding cleft. The middle of the peptide frequently
bulges out of the peptide-binding cleft. Bulging in the center
makes these residues more accessible to the TCR and as such
these residues are usually critical for TCR recognition (see Ref.
4 for review).
Class I MHC molecules are capable of binding a diverse set of
peptides with long half-lives. A major component of the binding
energy is derived from interactions between conserved residues
in the peptide-binding cleft and the invariant peptidic termini
(5). Additionally, peptides that bind with high affinity typically
have two or more relatively invariant residues, termed an-
chors, that bind in specificity pockets primarily composed of
class I heavy chain polymorphic residues (6–8). Other posi-
tions in the peptide can also make significant contributions to
peptide-MHC affinity (9).
Previously, we identified two aromatic single amino acid
substitutions at the amino-terminal end (P1 position, normally
isoleucine) of the HLA-A2.1 (A2)-restricted HIV reverse tran-
scriptase (RT) peptide-(309–317) (ILKEPVHGV) that increase
the cell surface half-lives of complexes 3-fold over the A2/RT-
peptide complex. These two peptides, designated I1F and I1Y,
also show increased immunogenicity compared with the wild-
type RT. In vitro experiments with peripheral blood lympho-
cytes (PBLs) from three different HIV-positive patients show
that in vitro expansion of CTL using I1Y-pulsed antigen-pre-
senting cells stimulates a higher CTL response against wild-
type RT-pulsed target cells than in vitro expansion with the RT
peptide itself. In contrast, I1F-pulsed cells stimulate a higher
response against RT-pulsed cells in only one of the two sets of
donor PBLs that were tested. The I1F and I1Y peptides also
differ in their ability to be recognized by RT-specific CTL lines
(10).
To understand better why the I1Y, I1F, and RT peptides
have differing immunological properties, we determined the
x-ray crystal structures of A2 complexed with I1Y and I1F
peptides to 2.2 and 2.8 Å resolution, respectively. Comparison
of these structures with the previously determined RT struc-
ture (5), along with modeling the interactions of the A6 and B7
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TCRs (11, 12) with the three A2 structures, has given us insight
into the differing immunological properties. The crystallo-
graphic structures suggest that the increases in cell surface
half-life are due to interactions between the aromatic P1 resi-
dues (Tyr and Phe) and tryptophan-167 of A2. Pseudo homol-
ogy models of TCR and these class I MHC complexes suggest
that the differences in T cell recognition between the I1Y and
I1F complexes may be attributed to two subtle structural dif-
ferences due specifically to the hydroxyl group of P1-tyrosine.
MATERIALS AND METHODS
Synthetic Peptides—All peptides were synthesized by the Peptide
Synthesis Facility at the University of North Carolina, Chapel Hill. The
sequences of the peptides are ILKEPVHGV (wild-type RT),
YLKEPVHGV (I1Y), and FLKEPVHGV (I1F). All peptides were puri-
fied by reverse-phase high pressure liquid chromatography to greater
than 95% purity, and the sequences were confirmed by matrix-assisted
laser desorption ionization-time of flight spectrometry.
Folding and Purification of A2 Complexes—A2/I1Y and A2/I1F com-
plexes were folded by rapid dilution in vitro as described previously
(13). After incubation for 36–48 h at 10 °C, the folding solutions were
concentrated in an ultrafiltration cell (Amicon; Beverly, MA) and puri-
fied by high pressure liquid chromatography-gel filtration chromatog-
raphy (Phenomenex, BioSep-SEC-S2000) in 50 mM Tris-Cl, pH 7.5, 150
mM NaCl. Purified complexes were then concentrated using Centri-
con-10 concentrators (Amicon) and exchanged into buffers consisting of
either 25 mM MES, pH 6.5, for crystallization, or 10 mM potassium
phosphate, pH 7.4, for circular dichroism experiments.
Thermal Stability of A2 Complexes—The relative stabilities of the
peptide/A2 complexes were measured by circular dichroism (CD) ther-
mal denaturation experiments. The experiments were performed on an
AVIV 62-DS spectropolarimeter equipped with a Peltier temperature
control unit. The protein concentration was approximately 10 mM in 10
mM potassium phosphate, pH 7.4. The thermal denaturation of purified
A2/RT, A2/I1Y, and A2/I1F complexes was monitored as the change in
circular dichroic signal at 218 nm from 4 to 95 °C. The Tm values (50%
denatured) were determined by modeling the denaturation as a two-
state process (14) from a normalized plot of the denaturation. The
reported Tm is the average of three separate thermal denaturation
experiments. The error associated with the reported Tm is the sum of
the machine error (0.5 °C) and the error in the curve fit (;0.5 °C).
Crystallization—Both A2/I1Y and A2/I1F complexes were crystal-
lized by the hanging drop vapor-diffusion method. The well solution for
A2/I1Y contained 18% PEG-8000 in 25 mM MES, pH 6.5, and the
hanging drop was a 1:1 mixture of the well solution and 10 mg/ml
protein in 25 mM MES, pH 6.5. The well solution for A2/I1F contained
20% PEG-8000 in 25 mM MES, pH 6., and the hanging drop was a 1:1
mixture of the well solution and 10 mg/ml protein in 25 mM MES, pH
6.5. Microseeding was performed for both complexes to obtain large
single crystals suitable for crystallographic studies.
Data Collection and Processing—Crystals were transferred directly
into cryoprotectant buffer containing 20% PEG-8000 supplemented
with 25–30% glycerol in 25 mM MES, pH 6.5, and placed directly into a
100 K nitrogen stream generated by an Oxford Cryo System. The
A2/I1Y diffraction data were collected on beamline X-12B at the Na-
tional Synchrotron Light Source (NSLS), Brookhaven National Labo-
ratories (Upton, NY). The A2/I1F diffraction data were collected on a
Rigaku R-Axis IIC using CuKa radiation. All diffraction data were
processed using the programs Denzo and Scalepack (15). Data statistics
are shown in Table I.
Structure Determination—The structures of both complexes were
determined using the Molecular Replacement method (AMoRe) with
the CCP4 program suite (16) using the A2/hepatitis B virus nucleocap-
sid peptide-(18–27) (FLPSDFFPSV) crystallographic structure (5) as
the search model (Protein Data Bank code PDB1HHH). As there are
two molecules per asymmetric unit of each crystal, 2-fold non-crystal-
lographic averaging coupled with solvent flattening and histogram
matching (DM) (17) greatly improved the quality of the electron density
maps. Manual model building into the electron density maps was per-
formed using the program O (18).
Refinement of A2/I1Y—Computational refinement was performed
using the programs X-PLOR version 3.851 (19) and Refmac (20) in
CCP4 (21). The structure was first refined in X-PLOR using 8–2.2-Å
resolution data. Two-fold non-crystallographic-symmetry (NCS) re-
straints were applied to the two molecules in the asymmetric unit of
A2/I1Y crystals with a weight of 300 kcal mol21 Å22. Overall isotropic
B factor refinement was first performed, followed by rigid body refine-
ment using three structural domains as follows: a1/a2 (the peptide-
binding superdomain), a3, and b2-microglobulin. Cycles of computa-
tional refinement were performed using positional refinement. Later
cycles of refinement were performed using Refmac with “strict” NCS
restraints (see Refmac manual), a bulk solvent correction, overall aniso-
tropic B factor correction, and individual B factor refinement. 192 water
molecules were added to the structure using program ARP (22) in CCP4
with Refmac as the refinement tool. The final Rfree (23) and Rwork factors
(F .0) between 30 and 2.2 Å are 28.9 and 24.4%, respectively. The
refinement statistics are shown in Table I.
The conformations of the peptides were confirmed by the following
“averaged” omit map procedure. The peptide was omitted from the
refined model before calculation of the phases and structure factors
used to generate the electron density map input into DM. Model masks
were made using peptide to be sure that all averaging included peptide
regions. Finally, model phase bias was reduced from the initial map in
DM by 2-fold non-crystallographic averaging, solvent flattening, and
histogram matching.
Refinement of A2/I1F—Refinement of A2/I1F was performed as was
A2/I1Y except Refmac was used throughout the refinement. Rigid body
refinement was used to optimize the domain positions. Cycles of posi-
tional refinement were performed with strict NCS restraints (see Ref-
mac manual), a bulk solvent correction, overall anisotropic B factor
correction, and overall temperature factor refinement. Final cycles in-
cluded individual temperature factor refinement. This was justified by
TABLE I
Summary of crystallographic statistics
Parameters A2/I1Y A2/I1F
Space group P1 P1
Cell dimensions a 5 50.61 Å a 5 49.57 Å
b 5 63.59 Å b 5 62.97 Å
c 5 75.33 Å c 5 74.56 Å
a 5 81.93 ° a 5 82.08 °
b 5 75.94 ° b 5 76.47 °
g 5 78.00 ° g 5 77.78 °
Molecules/AU 2 2
Resolution (Å) 2.2 2.8
Number of crystals 1 1
Rmerge (%)
a 7.3 (23.1)b 11.0 (32.0)
,I/G. 9.70 (2.60) 13.2 (4.1)
Unique reflections 45024 21030
Total observations 222078 148065
Completeness (%) 97.9 (96.4) 99.2 (98.6)
Refinement (F . 0)
Resolution (Å) 30–2.2 Å 15–2.8 Å
Rwork
c (no. of reflections) 24.4% (40,341) 27.4% (18,619)




No. of water molecules 192 NAf
Average B factor 21.7 43.2
,RSCC.d 87.3% 74.5%
Errore 0.20 Å 0.42 Å
r.m.s. deviations from
ideality
Bonds (Å) 0.010 0.009
Angles (°) 2.489 2.493
Dihedrals (°) 25.433 26.095
Impropers (°) 1.724 1.907
Residues in
Ramachandran plot (%)
Most favored 91.7 89.0
Additional allowed 8.0 10.6
Generously allowed 0.3 0.4
Disallowed 0 0
a Rmerge5¥hkl ¥i ?Ii 2 I?/¥hkl ¥i Ii, where Ii is the observed intensity
and is the average intensity of multiple observations of symmetry
related reflections.
b Number in parentheses refers to the highest resolution shell.
c R5¥hkl? ?Fobs?2k?Fcal? ?/¥hkl ?Fobs?, where Rfree is calculated for a
randomly chosen 8% of reflections; Rwork is calculated for the remaining
92% of reflections used for structure refinement.
d Real space fit correlation coefficient calculated in O (17).
e Error is the mean estimate of the positional error based on maxi-
mum likelihood methods calculated in Refmac (20).
f NA, not applicable.
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the observation of a drop in the Rfree. The final Rfree and Rwork factors (F
.0) between 15 and 2.8 Å are 31.5 and 27.4%, respectively. The refine-
ment statistics are shown in Table I.
RESULTS
Relative Thermal Stability by Circular Dichroism (CD) Anal-
ysis—The thermal stability of class I MHC molecules, as meas-
ured by circular dichroism (CD), is proportional to the free
energy of peptide binding (24). We used CD thermal denatur-
ation experiments to compare the relative thermal stability of
purified A2 folded in vitro with I1Y, I1F, and RT peptides.
A2/I1F and A2/I1Y complexes generated significantly higher
melting temperatures (temperature at which 50% of the com-
plexes have denatured) at 55 and 56 °C, respectively, compared
with 48 °C for A2/RT (Fig. 1). Therefore, both I1F and I1Y
peptides bind to A2 with higher affinity than RT. These results
are consistent with the increased cell surface half-lives we have
previously reported (10). In order to understand why they bind
with higher affinity, we determined their crystal structures
bound to A2.
Crystal Structures of A2/I1Y and A2/I1F—The x-ray crystal
structures of the A2/I1Y and A2/I1F complexes were deter-
mined to a resolution of 2.2 and 2.8 Å, respectively. Both
structures show clear, unambiguous density throughout the
model. Overall, the A2/I1Y and A2/I1F structures are very
similar to the RT structure (5) (r.m.s. deviations of 0.33 Å each
when superpositioning the a-carbons of the peptide-binding
super domains). The peptide positions are unambiguous in the
density. The averaged omit maps for the I1Y and I1F peptides
(see under “Materials and Methods”) are shown in Fig. 2, A and
B. Both the I1Y and I1F peptides bind in the cleft in a confor-
mation similar to that of the RT peptide, as shown in Fig. 2, C
and D. The I1Y and I1F peptides have r.m.s. deviations of 0.33
Å and 0.25 Å for the a-carbon backbone of the peptides alone,
respectively, based on the above superimposition of the a1/a2
domains onto the A2/RT a1/a2 domains.
Upon completion of the crystal structure determinations, we
looked for a reason for the increased affinity of the I1F and I1Y
peptides as compared with RT. As the overall structures of the
complexes are identical, we examined the peptides. In general,
the paths of the main chain atoms of the peptides are identical.
The side chain orientations of the P1 residues of the three
peptides are similar, with the side chain pointing out of the
binding cleft toward the TCR (Fig. 2, C and D). The aromatic
rings of phenylalanine and tyrosine of I1F and I1Y are both
oriented parallel to tryptophan-167 of the A2 binding cleft at a
distance of 3.5 Å, suggesting these P1 substitutions allow sta-
bilizing p-p orbital interactions with tryptophan-167. These
p-p stabilizing interactions are not possible with the isoleucine
in the wild-type peptide. The interaction of the P1 residue of
I1Y peptide with tryptophan-167 is shown in Fig. 3B.
Next, we asked why T cell recognition is increased for the
A2/I1F and A2/I1Y complexes compared with A2/RT. Exami-
nation of the structures shows one significant topological
change to the surface of the TCR contact region when compared
with the A2/RT complex. The P1 side chains I1Y and I1F
protrude farther out of the peptide-binding cleft. The increased
size of these amino acids increases the distance that the P1 side
chain protrudes from the binding cleft by 2.9 and 1.6 Å,
respectively.
The only other difference between the structures of the I1Y
peptide and the RT peptide, besides the substitution at the first
position, is at the P4 glutamate. In the A2/I1Y structure, the P4
glutamate moves 0.6 Å from the RT position toward the P1
tyrosine. The distance between the tyrosine hydroxyl and the
carboxylate of the glutamate is 5.7 Å and is too long for a direct
hydrogen bond. The averaged omit map shows an elongated
stretch of electron density perpendicular to the peptide back-
bone between the P1 and P4 residues, as shown in Fig. 4. This
region of density is large enough to accommodate up to three
waters at various occupancies. A water molecule within this
stretch of electron density would be sufficient to bridge a hy-
drogen bond interaction between the tyrosine and the gluta-
mate. However, the relatively low peak heights in the electron
density maps suggest that these waters are not highly occu-
pied. The side chain nitrogen of lysine-66 in the A2 binding
cleft is sufficiently close to participate in a hydrogen bond with
a water molecule that lies between the P1 and P4 residue as
well. Conversely, in the I1F structure the glutamate at position
4 moves 1.1 Å (relative to the RT position) toward the carboxyl-
terminal end of the peptide. Thus, the overall effect is to either
move the glutamate side chain toward the potential hydrogen-
bonding partner at P1 (in I1Y) or away from P1 (in I1F).
Modeling of TCR Interactions—In order to understand the
potential effects that the P1 substitutions would have on TCR
recognition, we modeled the P1 residues at the TCR/class I
interface. There is close similarity at P1-P2 of the Tax peptide
(leucine-leucine) in the TCR-MHC co-crystal structure (11, 12)
and the RT peptide (isoleucine-leucine). Therefore, the struc-
tures of human ab TCRs A6 (11) and B7 (12), both co-crystal-
lized with A2/Tax peptide (LLFGYPVYV), provide a good model
for comparing the TCR-MHC interactions between RT and
I1Y/I1F. Both TCRs were modeled onto the A2/I1Y, A2/I1F, and
A2/RT structures by superimposing the a1/a2 domains of our
structures onto the a1/a2 domains of A2/Tax complex in each of
the co-crystal structures. The r.m.s. deviations for the super-
imposition of the A2/TOX molecules in the A6 and B7 TCR
co-crystal structures onto A2/RT were 0.50 and 0.42 Å. A model
of the B7 TCR docked with A2/I1Y is shown in Fig. 3A. Inter-
atomic distances were calculated between the P1 peptide resi-
due and the nearest residue of the TCR and are summarized in
Table II.
There are no unfavorable van der Waals contacts between
the P1 isoleucine of RT and the two TCRs. However, the phe-
nylalanine of A2/I1F, makes one significantly bad van der
Waals contact with methionine 28 of the B7-TCR (2.11 Å as
compared with the optimal value of 3.4 Å). All of the potential
bad contacts of I1F with the A6 TCR are within experimental
FIG. 1. Circular dichroism experiments show that the I1F and
I1Y peptides stabilize A2 to higher temperatures than does RT.
The relative stabilities of the peptide-MHC complexes were measured
by circular dichroism thermal denaturation experiments. The thermal
denaturation of purified A2/RT (l), A2/I1Y (●), and A2/I1F (‚) com-
plexes (;10 mM) was monitored as the change in circular dichroic signal
at 218 nm from 4 to 95 °C. The Tm values (50% denatured) were
determined modeling the denaturation as a two-state process (14).
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error. The additional hydroxyl of the tyrosine side chain (I1Y),
as compared with I1F, increases the number of unfavorable van
der Waals contacts to five for the B7-TCR and three for the
A6-TCR. Collectively, these data suggest that the B7 and A6
TCR would not bind to these complexes because of the unfa-
vorable van der Waals contacts brought by the larger phenyl-
alanine and tryrosine side chains. This is not unexpected be-
cause the A6 and B7 TCR are not known to recognize A2/RT or
RT-variant peptide complexes. But, these data do suggest that
RT-specific TCRs could take advantage of these larger (and for
I1Y, more polar) P1 side chains to increase the TCR binding
affinity for the A2/I1Y and A2/I1F complexes.
DISCUSSION
The design of peptides with high affinity for class I MHC to
use in peptide-based vaccines requires a process of molecular
“fine-tuning.” In this process, the peptide must be altered in a
manner significant enough to increase the affinity of peptide
for MHC, but these changes must be also be subtle enough so
that the peptide-MHC complex is still recognized by the reper-
toire of TCRs that recognize wild-type peptide. Increases in
immunogenicity may be accounted for by the following three
non-exclusive mechanisms. 1) Changes to the peptide that in-
crease the stability of the peptide-MHC complex increase the
cell surface half-life of the complex. This would increase the
relative concentration of the peptide-MHC complex at the cell
surface and by standard equilibrium processes increase the
number of engaged MHC/TCR. 2) The increased concentration
of the complexes at the cell surface and association with the
membrane increases the avidity of the MHC-TCR interaction.
3) Changes in the peptide directly increase the affinity (or
duration of contact) of the peptide-MHC complex for TCR. In
this study, we have seen examples of all of these mechanisms.
We previously screened 11 different P1 substitutions of the
HIV-RT peptide for the ability to increase the A2/peptide com-
plex stability at the cell surface (10). P1 substitutions were
chosen in an effort to minimize alterations in T cell interac-
tions, given that structural data suggest the majority of the P1
residue is typically buried in the binding cleft (5). Two P1
substitutions, I1F and I1Y, increased the cell surface half-life of
the A2/peptide complex from 10 to 30 h (10). I1Y stimulated a
higher CTL response against wild-type RT-pulsed target cells
than the RT peptide itself.
These investigations raise several structural questions re-
garding the differing immunological properties between A2/RT,
A2/I1Y, and A2/I1F complexes. First of all, what features of the
A2/I1Y and A2/I1F complexes account for the drastic increase
in cell surface half-life? Second, how do we account for the
difference in immunogenicity of the two peptides, given that
the cell surface half-lives of the A2/I1Y and A2/I1F complexes
are nearly identical? Finally, how do we account for the differ-
ences in RT-specific CTL line recognition between I1Y and I1F?
To understand better the structural basis for the differing
immunological properties between A2/RT, A2/I1Y, and A2/I1F
complexes, we determined the x-ray crystal structures of the
A2/I1Y and A2/I1F complexes at 2.2- and 2.8-Å crystallographic
resolution, respectively. The 2.5-Å structure of A2/RT was de-
scribed previously by Madden et al. (5) and is used for compar-
ison with our models.
Biochemically, one of the striking differences between the
A2/RT and both the A2/I1Y and A2/I1F complexes is the dra-
matic increase in cell surface half-life. A significant feature
revealed in the A2/I1Y and A2/I1F crystal structures is the
parallel orientation of the aromatic P1 residues and Trp-167 at
a distance of 3.5 Å, which defines the peptide amino-terminal
end of the binding cleft (Fig. 3). Aromatic-aromatic interactions
FIG. 2. I1Y and I1F peptides assume the same main chain
conformations as the RT peptide within the peptide-binding
cleft of A2. The A2-binding cleft residues are omitted for clarity. The
orientation of the peptides is with the a2-helix in front of the plane of
the page, the a1-helix behind the plane of the page, and the b-sheet
domain below the peptide. A, 2 Fo 2 Fc averaged omit map of I1Y
peptide at a contour level of 1.4 s and a cover radius of 1.4 Å. B, 2Fo 2
Fc averaged omit map of I1F peptide at a contour level of 0.9 s and a
cover radius of 1.4 Å. C and D, the a1/a2 domains of A2/I1Y and A2/I1F
were superimposed onto the a1/a2 domain of the A2/RT structure (5),
with r.m.s. deviation values of 0.33 and 0.33 Å, respectively. Based on
this same superimposition, the r.m.s. deviation values for the a-carbon
backbone of the I1Y and I1F peptides relative to the RT peptide are 0.33
and 0.25 Å, respectively. C, comparison of the I1Y peptide (magenta)
and the RT peptide (yellow). D, comparison of the I1F peptide (cyan) and
the RT peptide (yellow).
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are a common mechanism in protein stabilization and are
estimated to contribute 21 to 22 kcal/mol binding energy (25).
It is likely that this feature of the A2/I1F and A2/I1Y complexes
accounts for the increased cell surface half-lives of the peptide-
MHC complexes. This is consistent with the 7–8 °C increase in
thermal stability observed in the CD thermal denaturation
experiments with the A2/I1F and A2/I1Y complexes.
The increase in cell surface half-life of the A2/I1Y complex is
probably an important determinant with respect to the in-
creased immunogenicity of A2/I1Y. The primary mechanism
could be postulated to be that the increase in the concentration
of the complex at the cell surface increases the potential num-
ber of class I complexes that interact with the TCR by thermo-
dynamic mechanisms. But it cannot be the entire story. Both
A2/I1Y and A2/I1F complexes have identical cell surface half-
lives of 30 h (compared with 10 h for the RT complex). However,
in in vitro experiments using PBLs from HIV-positive donors,
the I1Y peptide was able to stimulate a higher CTL response
against RT-specific target cells than RT peptide stimulation
itself in three of three PBL sets tested. On the other hand, I1F
stimulated a higher CTL response in the PBLs of only one of
the two donors tested. Changes to the affinity and/or duration
of contact between MHC-peptide and TCR must be involved.
There are two potential explanations for this phenomenon. The
first explanation is that all the TCRs of the T cells that respond
to A2/RT have increased affinity for (or prolong contact with)
A2/I1Y. It could also be that only a subset of T cells actually
respond to A2/I1Y, but the TCR have higher affinity for (or
prolonged contact with) A2/I1Y, and that interaction makes the
subset of T cells respond better then the full set of T cells to
A2/RT. Unfortunately, we cannot resolve these two possibilities
because the cell lines are extinct, and the donors are deceased.
Our crystallographic studies reveal that the A2/I1Y complex
has two significant structural differences from the RT and I1F
complexes that could affect TCR interactions. From our mod-
eling studies with the A6 and B7 TCRs onto the A2/RT, A2/I1F,
and A2/I1Y complexes, it is evident that the P1-Tyr of the
bound I1Y peptide protrudes far enough out of the binding cleft
to make significant unfavorable contacts with residues of the
TCR (Fig. 3). However, in the T cell repertoire that reacts to
RT-based peptides, it is a distinct possibility that the hydroxyl
group of P1-Tyr could make additional favorable hydrogen
bond interactions with the TCR that would not be permitted
with a phenylalanine or isoleucine at P1. Such interactions
could potentially increase the affinity or time of engagement of
the TCR-MHC interaction, which could in turn enhance the T
cell-mediated immune response.
A second feature of the A2/I1Y complex that differentiates it
from the I1F and RT complexes and may be involved in TCR
interactions is the interaction between the P1-Tyr and P4-Glu.
Comparison of the crystallographic structures of the A6 TCR/
Tax peptide/A2 complex versus the Tax/A2 complex alone dem-
onstrates that the middle of the Tax peptide undergoes a sig-
nificant conformational change upon TCR binding (11). This
FIG. 3. The P1 tyrosine of the A2/I1Y complex forms p-p stacking interactions with Trp-167 of A2 and has extensive contacts with
Met-28 in the CDR1a loop of the B7 TCR. A portion of the a chain (yellow) and b chain (green) of B7 TCR is modeled onto the a1/a2 domain
of A2 (cyan) and bound I1Y peptide (magenta) complex, as described under “Materials and Methods.” A, overall view of B7 TCR docked with the
A2/I1Y complex. B, enlarged view showing the interactions of P1-Tyr (magenta) with Trp-167 of A2 (cyan) and Met-28 of the B7 TCR (yellow). The
aromatic moiety of P1-Tyr (magenta) forms a stabilizing p-p orbital interaction with Trp-167 (cyan). The hydroxyl moiety of P1-Tyr makes
extensive contacts with Met-28 (yellow) of the B7 TCR. The distance shown is for the interaction of the P1-Tyr hydroxyl to the a-carbon of Met-28.
This interaction is one of five unfavorable van der Waals interactions between the two residues (summarized in Table II). All distances are in Å.
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suggests that some degree of conformational flexibility in the
bound peptide may be required for engagement of the TCR by
the MHC complex. The additional hydrogen bond interaction of
the P4-glutamate of the I1Y peptide with the P1-Tyr should
make the bound peptide more rigid than the I1F and RT pep-
tides, a factor that could easily alter T cell recognition. For
example, in the co-crystal structure of the TCR 2C and H-2Kb-
dEV8, there are six contacts between four residues on the
CDR3a loop with the P4 residue (26).
In summary, our data suggest that some of the increased
immunogenicity of the A2/I1Y complex is due to the increased
peptide-MHC affinity afforded by the aromatic substitution at
P1. At least part of the mechanism is due to increases in the
concentration of cell surface peptide-MHC and involves the
avidity of the MHC-peptide-TCR interaction. The modeling of
the TCR contacts and the differing biological reactivity be-
tween A2/I1F and A2/I1Y suggests that the interactions be-
tween the MHC and TCR are also affected. Thus, some part of
the increased immunogenicity must be due to increased affinity
(or duration of contact) between the peptide-MHC and the
TCR. The increases in immunological reactivity of I1Y and I1F
peptides are most likely due to a combination of equilibrium
mechanisms due to the increase in the density of complexes at
the cell surface and thermodynamic (or kinetic) mechanisms
due to the changes in the interface of MHC-peptide and TCR.
As these types of changes cannot easily be anticipated, altered
peptide ligands designed for immunotherapy must be carefully
examined biologically to test the effects of the changes made to
the peptide.
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TABLE II
Distances between atoms in residues of TCR models and
peptide P1 residues
Atom of Met-28 RT [C(d)] I1F [C(z)] I1Y [OH]
A. B7-TCRa
C(e) 5.94 4.62 4.06
S(d) 5.15 3.66 3.08
C(g) 3.73 2.11 1.38
C(b) 4.59 2.99 1.75
C(a) 4.29 3.00 1.98
N 5.37 4.27 3.37
C 4.79 3.55 2.45
O 4.46 3.23 2.25
Atom of Gly-28 RT [C(d)] I1F [C(z)] I1Y [OH]
B. A6-TCR
C(a) 4.32 2.94 1.88
N 5.62 4.30 3.24
C 4.62 3.30 2.13
O 4.03 2.82 1.91
a Interatomic distances between a chain Met-28 of B7-TCR and the
closest atom of the peptide P1 residue. Distances (Å) below the optimal
van der Waals contact distance (after factoring in coordinate error) are
underlined.
b Interatomic distances between a chain Gly-28 of A6-TCR and the
closest atom of the peptide P1 residue. Distances (Å) that are below the
optimal van der Waals contact distance (after factoring in coordinate
error) are underlined.
FIG. 4. Hydrogen bond interactions bridged by water between
the P1 tyrosine and the P4 glutamate affect peptide rigidity. The
I1Y peptide is shown in magenta, and the Lys-66 residue of the A2 a1
a-helix is shown in yellow. Other A2 binding cleft residues have been
omitted for clarity. In this orientation, the a1-helix is behind the plane
of the page and the a2-helix is in front of the plane of the page. Lys-66
is behind the plane of the page and behind the electron density that
presumably reflects relatively ordered waters. The averaged omit map
(green) is contoured at 1.1 s with a 1.0-Å cover radius. The area of
density between P1 and P4 is oriented perpendicular to the peptide
backbone with the upper portion of density lying behind the plane of the
page with the lower portion of the density in front of the plane of the
page. This density could accommodate up to three waters. The potential
position of one water is indicated by a red sphere with the distances
from this water to the P1 tyrosine, P4 glutamate, and Lys-66 residues
indicated.
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